Last reviewed · How we verify
Omeprazole, amoxicillin, clarithromycin
Omeprazole, amoxicillin, and clarithromycin is a marketed combination therapy by Forest Laboratories, positioned in the treatment of Helicobacter pylori infections. The key composition patent expires in 2028, providing a strong barrier to generic competition until then. The primary risk is the potential for increased competition once the patent expires.
At a glance
| Generic name | Omeprazole, amoxicillin, clarithromycin |
|---|---|
| Sponsor | Forest Laboratories |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection (PHASE2)
- Perioperative Oxaliplatin With S-1 Combined H. Pylori Eradication in the Management of Locally Advanced Gastric Cancer (PHASE2)
- Tegoprazan-Amoxicillin Dual Therapy vs. Bismuth Quadruple Therapy for H. Pylori Infection (TATH-1) (PHASE4)
- Drug Interaction Study on Linaprazan Glurate Capsules (PHASE1)
- Comparative Effectiveness of Triple Versus Quadruple Therapy in the Treatment of Helicobacter Pylori Induced Gastritis (PHASE4)
- Comparative Study Evaluating Safety and Effectiveness of ( Proton Pump Inhibitor Versus Vonoprazan ) Based Triple Therapy With or Without Zinc to Eradicate H. Pylori Infection (PHASE3)
- Personalized vs Standard of Care Treatment for Helicobacter Pylori Eradication Among Veterans (PHASE3)
- Study on The Efficacy and Safety of Vonoprazan-containing Berberine Triple Therapy in Helicobacter Pylori First-Line Eradication (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Omeprazole, amoxicillin, clarithromycin CI brief — competitive landscape report
- Omeprazole, amoxicillin, clarithromycin updates RSS · CI watch RSS
- Forest Laboratories portfolio CI